Anti-Inflammatory and Vasoprotective Activity of a Retroviral-Derived Peptide, Homologous to Human Endogenous Retroviruses: Endothelial Cell Effects

George J. Cianciolo*, Salvatore V. Pizzo

Department of Pathology, Duke University Medical Center, Durham, North Carolina, United States of America

Abstract

Malignant and inflammatory tissues sometimes express endogenous retroviruses or their proteins. A highly-conserved sequence from retroviral transmembrane (TM) proteins, termed the “immunosuppressive domain (ID)”, is associated with inhibition of immune and inflammatory functions. An octadecapeptide (MN10021) from the ID of retroviral TM protein p15E inhibits in vitro release of pro-inflammatory cytokines and increases synthesis of anti-inflammatory IL-10. We sought to determine if MN10021 has significant in vivo effects. MN10021, prepared by solid-phase synthesis, was dimerized through a naturally-occurring, carboxy-terminal cysteine. In vivo anti-inflammatory activity was determined using a murine model of sodium periodate (NaIO₄)-induced peritonitis. In vivo vasoprotective effects were determined using: (1) a carrageenan-induced model of disseminated intravascular coagulation (DIC) in mice; (2) a reverse passive Arthus model in guinea pigs; and (3) vasoregulatory effects in spontaneously hypertensive rats (SHR). In vitro studies included: (1) binding/uptake of MN10021 using human monocytes, cultured fibroblasts, and vascular endothelial cells (VEC); (2) gene expression by RT-PCR of MN10021-treated VEC; and (3) apoptosis of MN10021-treated VEC exposed to staurosporine or TNF-α. One-tenth nmol MN10021 inhibits 50 percent of the inflammatory response in the mouse peritonitis model. Furthermore, 73 nmol MN10021 completely protects mice in a lethal model of carrageenan-induced DIC and inhibits vascular leak in both the mouse DIC model and a guinea pig reverse passive Arthus reaction. MN10021 binds to and is taken up in a specific manner by both human monocytes and VEC but not by cultured human fibroblasts. Surprisingly, orally-administered MN10021 lowers blood pressure in SHR rats by 10–15% within 1 h suggesting a direct or indirect effect on the vascular endothelium. MN10021 and derived octapeptides induce iNOS (inducible nitric oxide synthase) mRNA in VEC and nitrate in VEC cell culture supernatants and protect VEC from induced apoptosis or necrosis. However, pretreatment of VEC with nitro-L-arginine methyl ester (L-NAME), while inhibiting the release of nitrate, does not block the anti-apoptotic effect of MN10021 and derived octapeptides suggesting that their potent vasoprotective and anti-inflammatory activity is not nitric oxide dependent.

Background

We previously reported that fluids from patients representing 15 different types of neoplasms contained proteins which were capable of inhibiting the in vitro responses of human peripheral blood-derived monocytes to chemotactic agents and that these anti-inflammatory proteins were antigenically related to the retroviral transmembrane protein p15E [1]. We also demonstrated that both serially-passaged and spontaneous murine tumors, as well as the plasma and urine of mice bearing spontaneous tumors, contained p15E-related anti-inflammatory proteins [2] and that p15E purified from the transmembrane proteins of various retroviruses inhibited inflammation in mice [3]. We subsequently identified a 26-amino acid region of p15E which is highly conserved in not only murine retroviruses, but also feline, bovine, avian, and primate retroviruses as well as the human retroviruses HIV and HTLV (human T-lymphotocytic leukemia) [4]. A synthetic peptide (CKS-17) corresponding to the first 17 amino acids of this conserved region of p15E, when conjugated to a carrier protein (BSA [bovine serum albumin] or HSA [human serum albumin]), inhibits a variety of immunological functions such as proliferation in response to mitogens or alloantigens [5]; production of cytokines such as TNF-α and IFN-γ [6,7,8]; production of superoxide anion [9]; NK cell activity [10]; polyclonal B cell activation [11]; generation of CTL activity [12]; and IL-1 mediated signal transduction [13]. CKS-17 also inhibits cell-mediated immunity in vivo [14]. This highly conserved 26-amino acid region of the retroviral transmembrane proteins is termed the “immunosuppressive region or domain” based on the inhibitory profile of CKS-17.

MN10021 is a homodimeric octadecapeptide, corresponding to the 17-amino acid sequence of CKS-17 with an additional (naturally-occurring) carboxy-terminal cysteine through which homodimers are readily formed. MN10021 has biological activities without any requirement for conjugation to a carrier protein such as was required for the monomeric CKS-17 peptide [15,16,17,18]. In the present study we demonstrated that MN10021 retains the in vitro immunosuppressive/anti-inflammatory profile of CKS-17 and that MN10021 also has significant in vivo immunosuppressive/anti-
inflammatory activity. The results of these studies and an unexpected result from a pharmacological profiling of MN10021 led us to examine vascular endothelial and smooth muscle cells as potential targets for MN10021 and related peptides. Our data suggest that while the ability of these peptides to induce vasorelaxant molecules such as nitric oxide (NO) may have therapeutic benefits, the potent anti-inflammatory activity of these peptides is probably unrelated to their ability to produce vasoprotective molecules such as NO.

Methods

Ethics Statement

All studies on human leukocytes were performed on cells obtained from healthy volunteers by Dr. Carlo DeCastro at Duke University under a Duke University Institutional Review Board (IRB)-approved protocol. All subjects read, signed and dated an Informed Consent Form, previously approved by the Duke University Institutional Review Board, and this signed consent was then witnessed and kept in a locked file by Dr. DeCastro according to the procedures approved by the Duke IRB. All mouse studies were carried out in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) at MacroNex Inc. at their facilities in Morrisville, NC. All guinea pig studies were carried out in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) at Pharmakon USA at their facilities in Waverly, PA. All rat studies were carried out in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) at PanLabs Inc., Bothell, WA at their facilities.

Cells and Reagents

Peripheral blood mononuclear cells (PBMC) and polymorpho-nuclear leukocytes (neutrophils) were prepared in the following manner. Citrated (10% v/v; acid-citrate dextrose [ACD]; Sigma, St. Louis, MO) human blood was obtained from healthy volunteers under informed consent and mixed with an equal volume of sterile, isotonic saline. Approximately 30 ml of the diluted blood in a 50-ml conical polypropylene centrifuge tube was underlaid with 20 ml of Histopaque® 1077 (Sigma, St. Louis, MO) and the tubes centrifuged for 40 min at 22°C and 400 x g. The mononuclear cells at the plasma-Histopaque® interphase were removed, washed 2X with sterile phosphate-buffered saline, pH 7.4 (PBS), washed once with Hanks Balanced Salt Solution (HBSS) or media (RPMI-1640), depending on their intended use, and then resuspended in either buffer or complete media. Neutrophils were isolated from the pellet of the density gradient separation by rapid (<20 s) hypotonic disruption of contaminating erythrocytes with 0.2% NaCl which was then made isotonic by addition of an equal volume of 1.6% NaCl. The lysis procedure was repeated once and the cells washed twice and resuspended in HBSS containing 10 mM HEPES, 0.1% BSA (low endotoxin; Sigma, St. Louis, MO), pH 7.2.

Pooled human umbilical vein endothelial cells (HUVEC; Clonetics®, Cambrex, East Rutherford, NJ) were obtained from and cultured according to the provided instructions using media and supplements obtained from Cambrex. Cells were generally used between passages 3 and 6. Human umbilical artery smooth muscle cells (HUASMC; Clonetics®, Cambrex, East Rutherford, NJ) were obtained from and cultured according to the provided instructions using media and supplements obtained from Cambrex. WI-38 human fibroblast cells (CCL-75™) were obtained from the ATCC (Manassas, VA) and grown according to ATCC supplied instructions.

Dexamethasone, acetaminophen, diclofenac, carrageenan, sodium periodate (NaIO₄), cytochalasin B, nitro-L-arginine methyl ester (L-NAME), and SQ 22536 were all obtained from Sigma-Aldrich, St. Louis, MO.

Media

Media for human PBMC culture was as follows: RPMI-1640 was supplemented with 100 μl penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, 1 mM Na pyruvate, 1% MEM non-essential amino acids, 25 mM HEPES (all from Sigma, St. Louis, MO) and 1% Nutridoma-HS (Boehringer Mannheim; Indianapolis, IN). Complete Medium is media supplemented with 5% heat-inactivated (56°C, 30 min) pooled human AB serum (Pel-Freez; Brown Deer, WI).

Synthetic Peptides

MN10021, a dimerized octadecapeptide, and MN20050, its reversed sequence control, were first prepared by solid-phase synthesis and reverse-phase HPLC (RP-HPLC) purification of the corresponding monomer peptides: NH₂-LQNRRLGLDLLFLKEGGL-COOH and NH₂-LGGEKLFLDDLGRNLQCL-COOH. The monomer peptides were allowed to spontaneously dimerize overnight by slow stirring at pH 9 and the resultant dimer peptides separated from monomer peptides by RP-HPLC. All peptides were >97% pure by reverse phase-HPLC and the correct molecular mass verified by mass spectrometry. An additional peptide, MN20054, was synthesized with the phenylalanine (Phe) at position 11 replaced by a tyrosine (Tyr) to allow radiolabeling with [125I]. This peptide was purified, dimerized, and re-purified as described for MN10021 and MN20050 above. Monomer peptide analogs of MN10021 were prepared by solid phase synthesis and reverse phase-HPLC purification by SynPep, CA. The following peptides were used: DUK0001, NH₂-GLDLLFLFK-COOH; DUK0004, acetyl-GLDLLFLFK-acetyl; DUK0005, acetyl-GLDLLFLFK-NH₂; DUK0006, NH₂-GLDLLFLFK-NH₂; DUK0007, acetyl-GLDLLYLK-NH₂.

Animals

Mice (CD-1) and guinea pigs (Hartley) were obtained from Charles River, Raleigh, NC, and Newfield, NJ and housed under NIH-approved standards. All studies were conducted under Institutional Animal care and Use Committee-approved protocols (MacroNex Inc., mice; Pharmakon USA, guinea pigs; and MDS-Panlabs, rats) with appropriate veterinary supervision.

Assays of Peptide Binding/Uptake

An analog (MN20054) of MN10021 was synthesized with a Tyr11 in place of the Phe11 and subsequently radiolabeled with [125I] (Perkin Elmer; Boston, MA) using the chloramine-T method. Human blood monocytes (purified by adherence to plastic; 10⁷/0.2 ml in PBS with 0.5% BSA, pH 7.5 in 12 x 75 mm polypropylene tubes) were incubated in triplicate at 37°C for 60 min with 40 pmoles [125I]-MN20054 (~20 Ci/mmole) in the presence or absence of a 100-fold molar excess of unlabeled peptide. Tubes were shaken gently during the incubation. The contents of each tube were layered onto a layer of 0.8 ml of 10% sucrose in polypropylene Eppendorf tubes and the tubes centrifuged for 3 min at 8,000 x g to separate cell-associated from free ligand. The tubes were then snap-frozen in a dry-ice/acetone bath and the bottom of the tube containing the cell pellet cut off and then counted in a gamma-scintillation spectrophotometer. In studies to determine how much of the uptake was due to endocytosis, binding/uptake was performed as described.
above with the exception that half of the monocytes were pretreated for 30 min at 37°C with cytochalasin B (10 µg/ml; Sigma; St. Louis, MO).

For binding/uptake studies on endothelial cell, HUVEC were grown to confluence in 12-well tissue culture plates. Forty pmol of \(^{125}\text{I}\)-MN20054 (~20 Ci/mmol) in PBS with 0.5% BSA, pH 7.5, was added in a volume of 1.0 ml in the presence or absence of a 100-fold excess of the indicated competitor. The plates were allowed to incubate for 1 h at 37°C on a rocking platform and the wells were aspirated and washed 3X with 2.0 ml of ice-cold PBS/BSA. One ml of 1.0 N NaOH was added to each well for 30 min at RT to solubilize the cells and then 0.9 ml was removed from each well and counted in a gamma scintillation spectrophotometer.

For binding/uptake studies on fibroblasts, WI-38 fibroblasts (CCL-75\(^{TM}\), ATCC) were grown to confluence in 12-well tissue culture plates. To each of triplicate wells was added 20 pmol of \(^{125}\text{I}\)-MN20054 in the presence of either buffer alone, a 100-fold molar excess of MN20054, or a 100-fold molar excess of MN10021. The plates were incubated for 60 min at 37°C with gentle rocking, the wells aspirated and quickly washed 3X with 2.0 ml each of ice-cold PBS/BSA and 1.0 ml of 1.0 N NaOH added to each well to solubilize the cells. Nine-tenths ml of solubilized cells was then removed from each well and cell-associated radioactivity determined by gamma scintillation spectrophotometry.

Mouse Inflammatory Peritonitis Model

Effects of test compounds on the inflammatory accumulation of monocytes/macrophages or neutrophils in vivo were determined using a mouse peritonitis model. Briefly, groups of five 6–8 week old CD-1 outbred mice (Charles River; Raleigh, NC) were injected intraperitoneally (i.p.) with 1.0 ml of a sterile inflammatory stimulus (NaIO4; 5 mM in sterile isotonic saline; Sigma; St. Louis, MO). This procedure results in a dramatic accumulation of neutrophils in the peritoneal cavity which peaks at 6–8 h post injection, followed by an accumulation of monocytes/macrophages which peaks at 48–72 h post injection. Mice were euthanized by CO2 asphyxiation at either 6 h (for neutrophils) or 48 h (for monocyte/macrophages), the peritoneal cavities lavaged with two 10-ml washes of heparinized (10 u/ml; Sigma; St. Louis, MO) HBSS containing 0.1% (w/v) BSA, the washes pooled, and total and differential cells counts determined for each pooled cell suspension. Each test material was evaluated in a group of five mice, each of which was injected subcutaneously in the thigh with 0.2 ml of test material in HBSS 24 h prior to the i.p. injection of the inflammatory stimulus.

Mouse Carrageenan-induced DIC Model

Groups of 10 male CD-1 mice were injected i.p. with 0.25 ml of either vehicle (PBS) or peptide in vehicle at varying times prior to the i.p. injection of 1.0 ml of carrageenan (0.45% [w/v] in PBS; Sigma). In experiments where serum cytokine levels were determined, groups of 5 mice were euthanized at 1-, 2-, 4-, 8-, and 24-h post injection of carrageenan, blood collected by cardiac puncture into heparinized syringes, and the resultant plasma stored at –80°C until assayed by ELISA. In the single carrageenan-induced DIC experiment where blood cell counts were determined, groups of 20 CD-1 mice were injected 18 h prior to an i.p. injection of carrageenan with either 1.0 ml i.p. saline or 1 mg (245 nmol) i.p. injected MN10021. At 1-, 2-, 4-, and 24-h post injection of carrageenan, five mice from each group were euthanized and heparinized blood samples collected from the heart using heparinized syringes for subsequent determinations of WBG (white blood cell) counts, RBC (red blood cell) counts, or PLT (platelet) counts.

Vascular Leak Assays

Vascular permeability in the mouse carrageenan-model of DIC was determined by measuring extravasation of \(^{125}\text{I}\)-BSA from the blood into the lungs. Groups of 5 CD-1 mice were pretreated with the indicated doses of MN10021 or vehicle (saline) injected i.p. 18 h prior to i.p. injection of carrageenan or saline. Twelve hours later the mice were each injected i.v. with 0.25 ml of saline containing 10\(^6\) cpm of \(^{125}\text{I}\)-BSA followed by an i.p. injection of 1.0 ml of either saline or 0.45% carrageenan. Twelve hours after i.p. injection of carrageenan or saline the mice were euthanized, the lungs collected, radioactivity determined by gamma scintillation spectrophotometry, and the percent increase in lung-associated radioactivity determined by comparing the radioactivity in the lungs of the carrageenan-injected animals with that in the lungs of the mice injected i.p. with saline. Twelve hours post carrageenan injection was chosen for measurement of vascular leak because experience had indicated that no deaths in the untreated groups would occur earlier than this time.

Vascular permeability was assessed in the reverse passive Arthus reaction as follows: Groups of 5 male Hartley guinea pigs were injected s.c. with 62.5 to 300 µg (15–61 nmol) of MN10021 or vehicle (saline). Eighteen hours later both flanks of the animals were shaved and 6.25 or 12.5 µl of rabbit anti-BSA antiserum was injected intradermally (i.d.) at two sites, one on each flank. The animals were then injected i.v. with 1 ml of PBS containing BSA (1 mg/ml) and Evans Blue dye (2 mg/ml; Sigma; St. Louis, MO). Six hours later the animals were euthanized, the skin removed, and the level of induration determined as the diameter (mm) of the extravasation for each site measured on the ventral surface of the skin.

SHR Rat Hypertension Model

As part of a general pharmacological screen, MN10021 was evaluated in a rat model of hypertension by MDS-PanLabs (Bothell, WA). Briefly, groups of 3 SHR (spontaneous hypertensive) rats were dose orally with either MN10021 (30 or 100 mg/kg; 7.3–24 µmol/kg) or, as a positive control, L-methyldopa (100 mg/kg; 474 µmol/kg). Blood pressure measurements were made by tail cuff at 1, 2, and 4 h post administration of test compounds. A decrease of ≥10% of the baseline systolic blood pressure is considered significant in this assay.

RT-PCR

Cells were cultured with various concentrations of test materials, either with or without stimulus, for varying times. The cells were collected, washed and total RNA isolated using the RNeasy Mini Kit (Qiagen; Valencia, CA). Following isolation the RNA was treated with 7 units of DNase 1 according to the RNase-Free DNase Set (Qiagen; Valencia, CA) protocol. Using these procedures we usually obtained ~50 µg of total RNA/10\(^7\) cells. cDNA was prepared from the isolated mRNA and RT-PCR performed on the target cytokines/chemokines/growth factors using appropriate primer pairs and a control primer pair for β-actin (all from R & D Systems; Minneapolis, MN). RT-PCR was generally performed for 30 cycles for β-actin and 35–45 cycles for iNOS and VEGF.

Apoptosis Assays in HUVEC

Apoptosis was measured in HUVEC using the Cell Death Detection ELISA\(^{TM}\) kit (Roche Diagnostics; Indianapolis, IN) according to the manufacturer’s instructions. This assay is based on a quantitative sandwich-enzyme-immunoassay using mouse monoclonal antibodies directed against both DNA and histones,
respectively. It allows the specific determination of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates (apoptosis) and in the supernatant of dying cells (necrosis). The apoptotic index (\(\Delta f\)) was calculated as

where treatment refers to use of a known apoptosis- or necrosis-inducing agent (staurosporine, TNF-\(\alpha\)).

Assay for NO Release
HUVEC were grown to 80–90% confluence in 12-well tissue culture plates using defined media provided by Cambrex and supplemented with 10% FBS. Triplicate wells were incubated with either media alone or media containing 50 \(\mu\)M of the indicated peptide. Supernatant samples were removed from each well at 6 h and 24 h post peptide addition and assayed for NO release as measured by the presence of nitrate (converted to nitrite) using a kit supplied by Oxford Biomedical Research (Rochester Hill, MI) according to the manufacturer’s instructions.

Statistical Analysis
Statistical analysis was performed using a Student’s \(t\) test. Values of \(p<0.05\) were considered significant.

Results
In Vitro Anti-inflammatory Profile of MN10021
MN10021 inhibits the production or blocks the activity of a number of potential inflammatory mediators such as TNF-\(\alpha\), IL-1, IFN-\(\gamma\) and IL-2 (6–8, 13, 15). However, there has never been a systematic examination of the \(\text{in vitro}\) effects of MN10021 on human blood leukocytes in which many of these potentially important, pro-inflammatory biological activities were examined on the same set of cells. We therefore isolated various human blood leukocytes from a large volume of blood and tested MN10021 and its control peptide, MN20050, at concentrations ranging from 10 nM to 100 \(\mu\)M. The results from a representative set of experiments are summarized in Table 1, in which the IC\(_{50}\) for MN10021 on various proinflammatory functions is listed. Since all the studies for each set were performed on blood cells from the same volunteer, we believe they provide a truly representative profile of the potential anti-inflammatory capabilities of MN10021. Similar results in these same assays were obtained on at least three additional occasions. MN20050, the reversed-sequence control peptide, had no reproducible inhibitory effect in any of these assays.

Effect of MN10021 in a Mouse Model of Inflammatory Peritonitis
The \(\text{in vitro}\) profile of MN10021 suggested that it might have useful anti-inflammatory activity \(\text{in vivo}\). The retroviral protein from which MN10021 is derived was first characterized as having anti-inflammatory activity in a mouse model of peritonitis induced by i.p. injection of an inflammatory stimulus [3]. As shown in Table 2, MN10021 has potent anti-inflammatory activity in this model in which the inflammatory accumulation of monocytes/macrophages is quantitated 48 h after i.p. injection of NaIO\(_4\), an oxidant known to induce an inflammatory peritoneal exudate [19].

MN10021 achieved a maximal 70% inhibition of inflammation at a dose of 4 \(\mu\)g (1 nmol) with an IC\(_{50}\) of 0.4 \(\mu\)g (0.1 nmol). MN20050, the control peptide, had no anti-inflammatory activity even at doses as high as 40 \(\mu\)g (10 nmol). The potency of the \(\text{in vitro}\) anti-inflammatory effects of MN10021 is illustrated by comparison of its activity with those of the steroid dexamethasone or the non-steroidal anti-inflammatory drugs acetaminophen or diclofenac. These three agents achieved somewhat similar or slightly higher maximal levels of inhibition of inflammatory cell accumulation than did MN10021 (75–95% versus 70% for MN10021); however, the doses of dexamethasone, acetaminophen, and diclofenac required to achieve maximal inhibition were 204, 6614, and 314 nmol, respectively. In contrast, maximal inhibition of inflammatory cell accumulation with MN10021 was achieved with only 1 nmol of peptide. Similarly, the IC\(_{50}\) for acetaminophen and diclofenac was 132 and 16 nmol respectively while that for MN10021 was only 0.1 nmol. The data presented here are from one experiment in which accumulation of monocytes/macrophages was quantitated 48 h after NaIO\(_4\) injection. Similar results were obtained on at least two other occasions with the same assay. Furthermore, similar results were also observed (data not shown) in two experiments in which neutrophil accumulation in the peritoneum was quantified 8 h after an i.p. injection of mice with NaIO\(_4\).

| Mediator/Function* | MN10021 | MN20050 |
|-------------------|---------|---------|
| TNF-\(\alpha\)     | 6.2     | NE      |
| IL-1\(\beta\)     | 17      | NE      |
| IL-6              | NE      | NE      |
| GM-CSF            | 8       | NE      |
| LTB\(_4\)         | 6.2     | NE      |
| PAF               | 12.5    | NE      |
| TF                | 12.5    | NE      |
| Chemotaxis        | 0.25    | NE      |
| Adhesion          | NE      | NE      |
| Platelet Aggregation | 5      | NE      |

NE = No Effect.

*Methods used described in Methods S1.
doi:10.1371/journal.pone.0052693.t001

Effects of MN10021 in a Carrageenan Model of DIC
MN10021 displayed potent anti-inflammatory activity in the induced peritonitis model as described above. We also tested MN10021 in a carrageen-induced model of paw inflammation in mice and found it to be equally active (data not shown). We therefore sought to determine whether MN10021 might be active in a mouse model in which DIC is induced by the i.p. injection of carrageenan. As shown in Figure 1A, CD-1 mice injected i.p. with carrageenan rapidly become sick and die within 24–72 h. In contrast, mice previously injected i.p. with 1 mg (245 nmol) MN10021 maintain a normal physical appearance and readily survive to at least 120 h (longest time observed). We next tested various doses of MN10021 to obtain an estimate for an IC\(_{50}\) for protection by MN10021 in this model. As illustrated in Figure 1B, a dose of 30 \(\mu\)g (7 nmol) of MN10021, injected 18 h prior to the injection of carrageenan, protects approximately 50% of the mice. A number of other anti-inflammatory agents were also tested, with no success, for their ability to protect mice in this model of DIC (data not shown). These included neutralizing monoclonal antibody (Mab) to TNF-\(\alpha\), neutralizing Mab to IL-1\(\beta\), dexamethasone, acetaminophen, diclofenac, indomethacin, naproxen, aminoxyguline, quinacrine, and staurosporine. Pentoxifylline, a drug used to treat peripheral tissue blood flow and reported to have some activity for inhibition of TNF-\(\alpha\) release, had some protective activity but never achieved >50% protection.
Effects of MN10021 on Cytokine Release in DIC Model

In order to determine whether MN10021 affected cytokine release under conditions where it protected mice in the DIC model, mice were treated with MN10021 or saline and 18 h later injected with carrageenan. At 1-, 2-, 4-, 8- and 24-h post carrageenan injection, levels of TNF-α (Figure 2A) and IL-6 (Figure 2B) were determined from plasma samples by solid-phase ELISA. As Figure 2A shows, there was a steady increase in the level of TNF-α in the untreated, carrageenan-injected mice over 24 h. This increase was substantially (~85%), but not completely blocked by pre-treating the mice with 1 mg of MN10021. In contrast to the data observed for TNF-α, in untreated mice injected with carrageenan, the increase in the plasma level of IL-6 peaked at 4 h and then declined ~75% over the next 20 h (Figure 2B). Pretreatment with 1 mg (245 nmol) of MN10021 blocked about 50% of the peak response of IL-6. Although we have not previously observed MN10021 inhibition of IL-6 in human monocytes, inhibition of IL-6 by MN10021 in this mouse model might be the result of different species or the fact that additional cell types might be targeted by the MN10021.

Effects of MN10021 on Hematological Parameters in DIC Model

We next examined several hematological parameters in the plasma of mice, untreated or treated with 245 nmol of MN10021, injected with a lethal dose of carrageenan. As shown in Figure 3A, mice injected with carrageenan experienced a sharp increase in white blood cell (WBC) counts at 2–4 h post injection followed by a gradual decrease back toward normal levels over the next 20–22 h. The mice injected with carrageenan also experienced a sharp (~80%) decrease in platelet (PLT) levels during this same timeframe (Figure 3B), with the levels remaining decreased during the entire 24 h observation period. There was no observed effect on red blood cell (RBC) counts during the 24 h of observation (data not shown). Treatment with an i.p. injection of 245 nmol of MN10021 18 h prior to injection with carrageenan prevented much of the leukocytosis and inhibited a large percentage of the early decrease in PLT counts, although the PLT count of the MN10021-treated mice did decrease slowly over the 24 h period to approximately 50% of normal.

Effects of MN10021 in Vascular Leak Assays

Mice injected with carrageenan eventually presented with a frothy pink exudate from their respiratory tract and necropsy of mice which had died demonstrated hemorrhage in various internal organs, most noticeably the lungs. We thus examined the effect of MN10021 on vascular leak in the lungs of mice injected with carrageenan (Figure 4). Groups of 5 CD-1 mice were pretreated with the indicated doses of MN10021 or

Table 2. Potency of MN10021 in Mouse Peritonitis Model of Inflammation.

| Agent     | Maximum Inhibition (%) | Dose Achieving Maximum Inhibition (µg/nmole) | IC₅₀ (µg/nmole) |
|-----------|------------------------|--------------------------------------------|-----------------|
| Dexamethasone | 75                     | 80/204                                    | ND              |
| Acetaminophen    | 95                     | 1000/6614                                 | 20/132          |
| Diclofenac     | 90                     | 100/314                                   | 5/16            |
| MN10021     | 70                     | 4/1                                       | 0.4/0.1         |
| MN20050     | NE                     | NA                                        | NA              |

ND = Not Determined.
NE = No Effect.
NA = Not Applicable.
doi:10.1371/journal.pone.0052693.t002
vehicle (saline) injected i.p. 12 h prior to i.p. injection of carrageenan or saline. Just prior to the injection of carrageenan and the saline injected group received an additional 1.0 ml i.p. injection of saline. At each of the indicated times one group for each of the treatment conditions was euthanized, plasma was collected by cardiac puncture into heparinized syringes, and the plasma was stored frozen at \(-80^\circ\)C. All samples were assayed for either (A) TNF-\(\alpha\) or (B) IL-6 concentration using a solid-phase ELISA per the manufacturer’s instructions. The data plotted are the mean values \(\pm\) SE. Error bars were calculated for all values and if not visible are contained within the symbol.

doi:10.1371/journal.pone.0052693.g002

In order to verify the inhibition of vascular leak by MN10021 in a second model, we tested MN10021 in a reverse passive Arthus reaction model in guinea pigs (Figure 5). Guinea pigs were injected s.c. with the indicated dose of MN10021 or vehicle (saline). Eighteen hours later both flanks of the animals were shaved and the indicated amounts of rabbit anti-BSA antiserum injected intradermally (i.d.) at two sites, one on each flank. The animals were then injected i.v. with 1 ml of PBS containing BSA (1 mg/ml) and Evans Blue dye (2 mg/ml). Six hours later the animals were euthanized by barbiturate overdose, the skin removed, and the diameter of the extravasation for each site measured on the ventral surface of the skin. As shown in Figure 5, either 250 or 500 \(\mu\)g of MN10021 completely blocked vascular leak in response to the lowest challenge dose (6.25 \(\mu\)l) of anti-BSA while only the highest dose of MN10021 completely blocked the higher challenge dose of 12.5 \(\mu\)l of anti-BSA. Thus, the ability of MN10021 to block vascular leak in this reverse passive Arthus reaction model appears to be dependent on both the dose of MN10021 and the dose of the challenge administered intradermally.

doi:10.1371/journal.pone.0052693.g003
In the presence of cytochalasin B, the uptake of MN20054 is inhibited by an i.p. injection of 1.0 ml of either saline or 1.0% carrageenan. Twelve hours later, the lungs were euthanized, the lungs removed, and the lung-associated radioactivity determined by gamma scintillation spectrophotometry. The increases in lung-associated radioactivity were calculated as the mean ± SE of the 5 measurements made. ** p < 0.01; * p < 0.05; NS = not significant. doi:10.1371/journal.pone.0052693.g004

Uptake of MN10021 by Human Monocytes and Endothelial Cells

The ability of MN10021 to inhibit vascular leak raised the question of whether it might be affecting not only blood leukocytes but also having a direct effect on vascular endothelial cells. We first sought to determine whether MN10021 bound to or was taken up by human blood monocytes or endothelial cells. An analog of MN10021, MN20054, was synthesized in which the amino acid Phe at the 11 position was replaced with a Tyr to allow the peptide to be labeled with \(^{125}\text{I}\). Binding isotherms using \(^{125}\text{I}\)-MN20054 and purified, blood-derived human monocytes indicated that \(^{125}\text{I}\)-MN20054 appeared to bind to a specific, saturable manner (data not shown). However, because of insolubility of MN10021 at lower temperatures, these studies were performed at 37°C which raised the issue of whether binding or uptake was measured. Using a dose of \(^{125}\text{I}\)-MN20054 that gave maximal cell-associated activity, we examined the association of \(^{125}\text{I}\)-MN20054 with human monocytes in the presence or absence of a 100-fold molar excess of either unlabeled MN20054 or unlabeled MN10021 (Figure 6A). As the data indicate, the binding or uptake of \(^{125}\text{I}\)-MN20054 is inhibited by ~85% by unlabeled MN20054 and by ~65% by unlabeled MN10021. The unlabeled peptide MN20050 (reverse sequence) inhibited cell association of \(^{125}\text{I}\)-MN20054 by <10%. In order to determine whether the cell-associated radioactivity represented binding or uptake, the same experiment was performed in the presence of cytochalasin B to inhibit uptake. As shown in Figure 6B, in the presence of cytochalasin B there is a ~40% reduction in the amount of \(^{125}\text{I}\)-MN20054 associated with the monocytes that is not inhibited by MN10021. Thus a significant portion of the association of MN10021 with human blood monocytes appears to be binding, rather than uptake and internalization.

We next sought to determine if MN10021 also associated with human vascular endothelial cells. Using the same methodology as used for monocytes, \(^{125}\text{I}\)-MN20054 was incubated with HUVEC in the presence or absence of a 100-fold excess of unlabeled MN20054 or MN10021. As shown in Figure 6C, there is demonstrable association of \(^{125}\text{I}\)-MN20054 with HUVEC which is substantially inhibited (84 and 77%) by unlabeled MN20054 and MN10021, respectively, while there was no significant inhibition by the control peptide, MN20050. Thus MN10021 also binds to or is taken up by human vascular cells.

Although we did not specifically examine binding of \(^{125}\text{I}\)-MN20054 to human lymphocytes, we have reported the biological effects of MN10021 on human T- and B-lymphocyte responses and NK cell responses as well as on a murine T-cells [10,11,12,15] suggesting that the peptides either bind to or are taken up by these non-adherent cells. In order to determine if \(^{125}\text{I}\)-MN20054 binds to human fibroblasts we utilized the human fibroblast cell line WI-38. As shown in Figure 7, while the binding/uptake of \(^{125}\text{I}\)-MN20054 by HUVEC was inhibited ~75% by a 100-fold excess of either unlabeled MN20054 or MN10021, the binding/uptake of \(^{125}\text{I}\)-MN20054 by the WI-38 cells was unaffected by the 100-fold excess of either unlabeled peptide, suggesting that all of the binding/uptake is non-specific. This result, although with human-derived cells, would seem to support previous studies demonstrating a lack of effect by this peptide sequence on either murine fibroblast proliferation [3,20] or protein synthesis [21].

Effects of Oral MN10021 on Blood Pressure in SHR Rats

As part of a general pharmacological screen, MN10021 was tested in a SHR rat model for measuring anti-hypertensive activity of compounds. Groups of three SHR rats were orally-dosed (by gavage) with MN10021 (30 or 100 mg/kg). Blood pressure measurements were made at 1, 2 and 4 h using a tail-cuff manometer. As shown in Figure 8, 100 mg/kg (24 μmol/kg)
MN10021, dosed orally, causes a rapid 12% decrease in blood pressure within 1 h of oral dosing and reaches a maximal decrease of 15% within 2 h. At 4 h, the maximal time observed, there was still a 13% decrease in blood pressure from baseline levels. At the 30 mg/kg dose of MN10021 there was detectable but minimal (3–4%) decreases in blood pressure at the three time points measured (data not shown). The positive control L-methyldopa, dosed orally at 100 mg/kg (474 mmol/kg), lowered blood pressure by 16, 23, and 28% at 1, 2, and 4 h, respectively (data not shown).

Stimulation of inducible nitric oxide synthase (iNOS; NOS2) in HUVEC by MN10021

One mechanism by which a compound might lower blood pressure is to induce the release of nitric oxide (NO) into the blood. Since MN10021 had been found to bind to or be taken up by endothelial cells and since endothelial cells are a known source of NO, we examined the effect of MN10021 on the induction of mRNA for iNOS in HUVEC. HUVEC were incubated for 3 h with MN10021 and the mRNA for iNOS examined using RT-PCR. As shown in Figure 9A, MN10021 induces mRNA for iNOS within 3 h.

Identification of Potential Active Site in MN10021

MN10021, dosed orally, causes a rapid 12% decrease in blood pressure within 1 h of oral dosing and reaches a maximal decrease of 15% within 2 h. At 4 h, the maximal time observed, there was still a 13% decrease in blood pressure from baseline levels. At the 30 mg/kg dose of MN10021 there was detectable but minimal (3–4%) decreases in blood pressure at the three time points measured (data not shown). The positive control L-methyldopa, dosed orally at 100 mg/kg (474 mmol/kg), lowered blood pressure by 16, 23, and 28% at 1, 2, and 4 h, respectively (data not shown).

Stimulation of inducible nitric oxide synthase (iNOS; NOS2) in HUVEC by MN10021

One mechanism by which a compound might lower blood pressure is to induce the release of nitric oxide (NO) into the blood. Since MN10021 had been found to bind to or be taken up by endothelial cells and since endothelial cells are a known source of NO, we examined the effect of MN10021 on the induction of mRNA for iNOS in HUVEC. HUVEC were incubated for 3 h with MN10021 and the mRNA for iNOS examined using RT-PCR. As shown in Figure 9A, MN10021 induces mRNA for iNOS within 3 h.

Identification of Potential Active Site in MN10021

MN10021 dosed orally caused a rapid (1 h) drop in blood pressure in SHR rats (Figure 8). It seemed unlikely that MN10021, a dimerized octadecapeptide, would enter the bloodstream intact within this short period of time. Moreover, we presently have no...
evidence that MN10021 is absorbed rapidly through the oral or gastric mucosa and in the study of Figure 8, the MN10021 was delivered by gavage, bypassing the oral mucosa. We therefore next considered what fragment(s) of MN10021 might survive degradation in the gastrointestinal tract and be absorbed into the bloodstream and determined that the portion of MN10021 flanked by Arg-Arg on the amino terminus and by Lys on the carboxy terminus would be most likely to survive. The first peptide fragment we tested was an 8-amino acid peptide, GLDLLFLK, termed DUK0001. Incubation of DUK0001 with HUVEC for 3 h, as was done with MN10021, resulted in a weak induction of mRNA for iNOS but increasing the time of incubation to 5 h (data not shown) or making modifications to increase the solubility or stability of the peptide resulted in a much stronger induction (Figure 9A). These modifications included acetylation of both the amino- and carboxy-terminus (DUK0004), acetylation of the amino-terminus and amidation of the carboxy-terminus (DUK0005), and amidation of both the amino- and carboxy-termini (DUK0006). As shown in Figure 9B, although DUK0004 is the least soluble of these three peptides and DUK0006 is the most soluble, they are comparable in their abilities to induce iNOS in HUVEC. DUK0005, which is intermediate of the three peptides in solubility, is the most effective in inducing iNOS.

Neither MN10021 nor DUK0005 affected the expression of mRNA for endothelial nitric oxide synthase (eNOS) which was constitutively expressed in HUVEC (data not shown).

Activity of DUK0005 is Sequence Specific

In order to verify that the iNOS-inducing activity of DUK0005 was related to the specific amino acid sequence, an analog (DUK0007) was prepared and tested in which the Phe at the 6 position was replaced by a Tyr. This change results in the replacement of one hydrophobic amino acid with another hydrophobic amino acid but one that contains an additional hydroxyl group. As shown in Figure 9C, DUK0007, which is structurally-identical to DUK0005 except for the replacement of the Phe by the Tyr, does not induce iNOS in treated HUVEC. Interestingly, when DUK0007 is combined 1:1 with DUK005, it inhibits the induction of iNOS by DUK005 (data not shown) suggesting that it might bind or be taken up by the cells but acts as a competitive antagonist. However, we have not ruled out that this might simply be due to peptide-peptide interactions.

MN10021 and DUK0005 Protect HUVEC from Apoptosis

Although NO associated with inflammatory reactions is often considered to be pro-apoptotic, there are a number of studies indicating that low or physiological levels of NO can prevent apoptosis and can be vasoprotective in various in vivo situations. We, therefore, examined the ability of MN10021 and DUK0005 to protect treated HUVEC against staurosporine-induced apoptosis. As shown in Figure 10A, MN10021 added to HUVEC 3 h after MN10021 addition.
before the addition of staurosporine (100 or 500 nM) resulted in a significant protection against staurosporine-induced apoptosis measured at 24 h after staurosporine addition. Attempts to measure apoptosis of HUVEC treated with TNF-α were unsuccessful in that the TNF-α caused a rapid necrosis of the HUVEC. However, even in this situation, pretreatment of the HUVEC with MN10021 for 3 h prior to addition of the TNF-α resulted in a significant protection against the necrosis-inducing effects of the TNF-α (Figure 10B). Treatment of HUVEC with DUK0005 for 3 h prior to addition of staurosporine also resulted in a dose-dependent inhibition of apoptosis (Figure 10C) although the maximal protection afforded by DUK0005 (~40%) was less than the maximal protection afforded by MN10021 (~60%) as shown in Figure 10A. An explanation for this difference in protection has not yet been determined.

Does NO synthesis correlate with vasoprotection
MN10021 and DUK0005 both induced iNOS mRNA and both protected against staurosporine-induced apoptosis, but we had not actually demonstrated NO release by these peptides. In order to verify that the induction of iNOS by these peptides is accompanied by the release of NO, we measured the release of nitrate into cell culture supernatants of HUVEC that had been incubated with peptides. As shown in Figure 11A, peptides MN10021, MN20054, and DUK0005, which either induced iNOS when incubated with HUVEC (MN10021 and DUK0005) or competed for binding with MN10021 (MN20054), all induced nitrate release (as measured by nitrite assay) from HUVEC incubated for either 6 h or ON with 50 μM peptide. The control peptide MN20050 (reverse sequence), which does not compete for [125I]-MN20054 binding and has no significant biological activity, and the DUK007 peptide, which did not induce iNOS after 3 h of incubation with HUVEC, both induced a small amount (~25% of MN10021) of nitrate release after 6 h and ON incubations. Whether this nitrate was the result of iNOS induction is unknown. We, therefore, examined the ability of MN10021, MN20054 and DUK0005 to protect treated HUVEC against staurosporine-induced apoptosis. As shown in Figure 11B, addition of MN10021, MN20054, or DUK0005 to HUVEC 3 h before the addition of staurosporine (500 nM) resulted in a significant protection against staurosporine-induced apoptosis measured at 18 h after staurosporine addition. The addition of either MN20050 or DUK007, neither of which produced significant NO, had no protective effect against staurosporine-induced apoptosis.

Protective effect of peptides is not NO-dependent
In order to confirm that the protective effects of MN10021, MN20054, and DUK0005 against staurosporine-induced apoptosis were the result of NO-induction, we pretreated HUVEC with L-NAME and then peptides prior to addition of staurosporine. As shown in Figure 12, pretreatment with the inhibitor of iNOS induction had no effect on the protective effects of MN10021, MN20054 or DUK0005. Under these same conditions the release of NO into the media by the peptides was blocked by the pretreatment with L-NAME (data not shown).

Discussion
Over two decades ago we first identified that human tumors produced anti-inflammatory proteins that were antigenically-related to the retroviral transmembrane (TM) protein p15E [1] and that p15E-related antigens were expressed not only in human tumors but in mitogen-transformed blood lymphocytes as well [22]. We subsequently showed that p15E itself had potent anti-
inflammatory activity in a murine model of induced peritonitis [3] and that p15E contained a sequence of 26 amino acids that is highly-conserved amongst all the TM proteins of retroviruses, both in humans and other species [4]. Studies using a nonomeric heptadecapeptide (CKS-17), corresponding to the first 17 amino acids of this highly-conserved domain (the “immunosuppressive domain”) and coupled to a carrier protein, have demonstrated both in vitro and in vivo activities, including inhibition of a wide variety of immunological functions [5,6,7,8,9,10,11,12,13].

MN10021, the homodimeric octadecapeptide, corresponding to the 17-amino acid sequence of CKS-17 with an additional (naturally-occurring) carboxy-terminal cysteine though which homodimers are readily formed, displays all of the biological activities of carrier-coupled CKS-17. It has been used to examine the molecular basis of the in vitro activities of these highly-conserved retroviral sequences [15,16,17,18]. In these studies we now report for the first time a comprehensive pharmacological profile of MN10021 on human peripheral blood-derived leukocytes. The in vitro anti-inflammatory profile exhibited by MN10021 in Table 1 would suggest that it might have in vivo anti-inflammatory activity as well. Indeed, as shown in Table 2, MN10021 is a potent anti-inflammatory agent in a murine model of induced peritonitis. On a molar basis it is several orders of magnitude more potent than known anti-inflammatory compounds such as dexamethasone, acetaminophen or diclofenac.

One of the more interesting observations to emerge from these studies were the data shown in Figure 1 demonstrating the ability of MN10021 to protect mice from a lethal dose of carrageenan in a model that closely mimics disseminated intravascular coagulation (DIC). MN10021 dramatically inhibited (>80%) the large increase in serum TNF-α levels (>20 ng/ml) associated with a lethal outcome in this model (Figure 2A). The observation that neutralizing monoclonal antibodies to TNF-α did not protect in this model suggested that additional factors were involved. MN10021 also inhibited, but to a lesser extent (∼50%), the transient increase in IL-6 levels which also occurred in this model. The ability of MN10021 to inhibit both the leukocytosis and the thrombocytopenia in mice injected with a lethal dose of carrageenan (Figure 3A, 3B) suggests that its protective effect may be reflective of a broad array of activities, including its ability to inhibit in vitro both ADP- and epinephrine-induced human platelet aggregation (data not shown).

In both the carrageenan-induced DIC model and the guinea pig reverse passive Arthus reaction model, MN10021 afforded significant protection against vascular leak (Figures 4 and 5). Although the exact mechanism of this protection remains to be determined, these observations led us to examine vascular cells as potential targets for MN10021 and related sequences. Using a radiolabeled analog of MN10021, we demonstrated that MN10021 binds to or is taken up in a specific manner not only by human blood monocytes but also by human endothelial cells while the observed binding to human fibroblasts appears to be non-specific. This latter result is in agreement with previous results indicating a lack of effects by this peptide sequence on murine fibroblasts [5,20,21]. The ability of MN10021 to prevent vascular leak and to bind to vascular endothelial cells, coupled with the surprising observation that orally-dosed MN10021 lowers blood pressure in SHR rats within 1 h of oral-dosing, suggested that the anti-inflammatory activity of MN10021 might be related to its ability to maintain vascular integrity under inflammatory conditions. Since leukocytes may extravasate from the blood to sites of inflammation, a compound which protects the vascular endothelium might also be expected to be anti-inflammatory.
The ability of MN10021 to significantly lower blood pressure within 1 h of oral dosing suggested a potent vasodilatory effect. One of the most potent vasodilators known is nitric oxide (NO), first described as EDHF (endothelial-derived relaxation factor). Our studies show that a 3 h treatment of HUVEC with MN10021 upregulates mRNA for iNOS, the inducible enzyme responsible for the synthesis of NO in a variety of cell types such as monocytes/macrophages, endothelial cells, and vascular smooth muscle cells. These results led us to test the hypothesis that the ability of MN10021 to lower blood pressure in SHR rats is the result of induced synthesis of NO. Our hypothesis was supported by previous work by others. Although supra-normal levels of NO, often found in inflammatory lesions, are generally considered to be deleterious, low or physiological levels of NO are vasoprotective [23,24,25]. For example, physiological levels of NO have been reported to attenuate: IL-2-induced lung injury in rats [26]; phorbol ester-induced microvascular permeability in dogs [27] and hydrogen peroxide-induced vascular permeability in rabbits [28]; leukocyte adhesion and vascular leak after myocardial ischemia [29]; platelet aggregation and adherence to sites of injury on endothelial cells [30,31,32,33,34,35]; upregulation of cell adhesion molecules (CAM) on endothelial cells [36,37,38,39]; and vascular smooth muscle cell proliferation and migration [40,41,42]. Furthermore, NO inhibits leukocyte migration in a rat carrageenan-induced pleurisy model [43]. A subsequent study by different investigators, utilizing inhibitors of NOS in a rat carrageenan-induced pleurisy model, demonstrated that local production of NO was protective by virtue of its ability to regulate the release of inflammatory mediators and that NOS inhibitors had differential anti-inflammatory effects depending on their route of administration [44]. Although we have detected s.c.-injected MN10021 in the blood of mice within 15 min (data not shown) we have no evidence that MN10021 is readily absorbed through oral or gastric mucosal surfaces. We, therefore, began to investigate whether analogs of MN10021, representing small fragments which might survive the harsh environment of the stomach, could also induce mRNA for iNOS. We identified an 8-amino acid peptide, DUK0005, which is as effective as MN10021 in inducing iNOS mRNA in HUVEC and HUASMC. Of particular interest, other investigators previously reported that a similar peptide corresponding to the central six amino acids of DUK0005, LDLLFL, inhibited iNOS human monocye monochromatic responses and ligand (CD8) and interleukin-2 (IL-2)-induced lymphocyte proliferation [45,46]. However, these same investigators did not find this hexapeptide to be anti-inflammatory in either mice or guinea pigs although they did present several possible explanations [47].

Additional investigators have also identified p15E-derived peptides, partially homologous to MN10021, which have immunomodulator activities. A recent study reported on studies utilizing a peptide (analog 3; LDLLFLKEGGL) which differs from our DUK0005 in that it is missing the Gly on the amino terminus and it contains the additional four amino acids (EGGL) on the carboxy terminus [48].

In addition to the above-listed protective effects which have been reported for NO, physiological levels of NO have been shown to inhibit apoptosis in a number of cell types, including leukocytes [49,50,51,52], hepatocytes [53,54,55,56,57], trophoblasts [58,59] and endothelial cells [60,61,62,63,64,65]. We therefore investigated whether MN10021 or DUK0005 could prevent apoptosis induced in HUVEC by staurosporine, a potent inhibitor of protein kinase C. Indeed, both MN10021 and DUK0005 protect against staurosporine-induced apoptosis in HUVEC. Although the percent inhibition of apoptosis was ~60% and ~40% for MN10021 and DUK0005, respectively, staurosporine is an extremely potent inducer of apoptosis with a very steep dose curve after a threshold dose concentration is attained. Thus, it is uncertain whether staurosporine-induced apoptosis is representative of what might occur with vascular cells under inflammatory conditions. In contrast, while TNF-α, in the absence of added cycloheximide, did not readily induce apoptosis, it did cause necrosis of HUVEC as measured by the release into the supernatant of histone/DNA fragment complexes. MN10021 was able to block almost completely, in a dose-dependent manner, this TNF-α-mediated necrosis of HUVEC. Of interest, in preliminary in vivo studies with MN10021 and DUK0005, intraperitoneal injection of 1 μg of either peptide was able to inhibit the vascular leak in the liver of mice injected intravenously with dengue virus.

We have now confirmed the release of NO with our peptides (MN10021 and DUK0005; Figure 11A) which induced iNOS mRNA as well as with MN20054 which competes for MN10021 binding. We have also demonstrated that these same peptides protect against staurosporine-induced apoptosis (Figure 11B) while our peptides (MN20050 and DUK007) that produced reduced amounts of NO (Figure 11A) had no protective effect against staurosporine. However, when HUVEC were pretreated with the inhibitor of iNOS, L-NAME, the protective effects of MN10021, MN20050, and DUK005 were not affected (Figure 12) even though NO release was blocked. Thus, the vasoprotective effects of these retroviral-derived peptide sequences appear to be independent of their ability to produce NO.

We and others have previously reported association of retroviral p15E-related proteins with a variety of human neoplasms and certain normal tissues [1,22,66,67,68,69]. In addition, human endogenous retroviruses (HERV) encoding for membrane proteins which contain the highly-conserved region from which MN10021 is derived, have also been identified in both normal and malignant human tissues [70-73]. A protein or peptide with both anti-inflammatory and vasoprotective properties might be expected to confer a selective advantage to malignant cells expressing it.
Such anti-inflammatory/vasoprotective proteins or peptides could also play a natural role as immunoregulators, limiting the extent of inflammatory reactions under all but the most intense situations. It is of interest that Katsumata et al. [78] have shown that inflammatory cytokines, such as IL-1 or TNF-α, can upregulate the mRNA for the human endogenous retrovirus HERV-R (ERV3) in human vascular endothelial cells since we had previously reported that endothelial cells treated for 4 h with IL-1 released anti-inflammatory proteins which reacted with anti-p15E antibodies [85]. We have recently found that rabbit antiserum raised against the MN10021-homologous region of p15E antibodies [85]. We have recently found that rabbit antiserum raised against the MN10021-homologous region of p15E antibodies [85]. We have recently found that rabbit antiserum raised against the MN10021-homologous region of p15E might share not only sequence homology (≈60%) but conformational homology as well.

Although our data initially suggested that the anti-inflammatory/vasoprotective effects of MN10021 might be due to its induction of NO, additional studies have now shown that NO induction by these peptides is not required for their in vitro vasoprotective effects. Further studies on these peptides will be necessary to determine the mechanism(s) involved in their vasoprotection and whether vasoprotection is the basis for their potential anti-inflammatory effects.

Conclusions

A transmembrane domain from retroviruses, including those from humans, has been conserved over a considerable time period on the evolutionary scale. This suggests that these sequences possess highly significant in vivo activities either of the type shown here or perhaps others as yet unknown. Peptides corresponding to these conserved regions have a variety of immunosuppressive, anti-inflammatory and vasoprotective effects. The exact role these sequences play in normal homeostasis and disease pathogenesis will be the object of further studies.

Supporting Information

Methods S1 The methods used to generate the data concerning the effects of MN10021 and its control peptide, MN20050, on human mononuclear cells as presented in Table 1 are described in detail in Methods S1.

(DOCX)

Acknowledgments

The authors wish to acknowledge the assistance of Ms. Fang Wang of the Department of Pathology at Duke University for her excellent technical assistance in the performance of the RT-PCR studies, the apoptosis studies, and the NO assays and Mr. Steven Conlon of the Duke Department of Pathology PhotoPath group for preparation of figures. We also wish to thank Michael Schlict, Jill Stuttman, Henry Wong, Jose-Luis Diaz and Ronald Uhing, all of MacroNex, in the performance of the animal and binding/uptake studies reported herein.

Author Contributions

Conceived and designed the experiments: GJC SVP. Performed the experiments: GJC. Analyzed the data: GJC. Contributed reagents/materials/analysis tools: GJC SVP. Wrote the paper: GJC SVP.

References

1. Cianciolo G, Hunter J, Silva J, Haskill J, Snyderman R (1981) Inhibitors of monocyte responses to chemotaxis are present in human cancerous effusions and react with monoclonal antibodies to the p15E structural protein of retroviruses. J Clin Invest 68: 831–844.
2. Cianciolo G, Herberman R, Snyderman R (1980) Depression of murine macrophage accumulation by low-molecular-weight factors derived from spontaneous mammary carcinomas. J Natl Cancer Inst 65: 829–834.
3. Cianciolo G, Matthews T, Bolognesi D, Snyderman R (1980) Macrophage accumulation in mice is inhibited by low molecular weight products from murine leukemia viruses. J Immunol 124: 2900–2905.
4. Cianciolo G, Kipnis R, Snyderman R (1984) Similarity between p15E of murine and feline leukemia viruses and p21 of HTLV. Nature 311: 515.
5. Cianciolo G, Copeland T, Oroszlan S, Snyderman R (1985) Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 230: 453–455.
6. Haraguchi S, Good R, Cianciolo G, Day N (1992) A synthetic peptide homologous to retroviral envelope protein downregulates TNF-α and IFN-γ gene expression. J Leuk Biol 52: 469–472.
7. Ogawasawa M, Cianciolo G, Snyderman R, Mitani M, Good R, et al. (1988) Human gamma interferon production is inhibited by a synthetic peptide homologous to retroviral envelope protein. J Immunol 141: 614–619.
8. Haraguchi S, Good R, Cianciolo G, James-Yarish M, Day N (1993) Transcriptional downregulation of tumor necrosis factor-α gene expression by a synthetic peptide homologous to retroviral transmembrane protein. J Immunol 151: 2733–2741.
9. Harrell R, Cianciolo G, Copeland T, Oroszlan S, Snyderman R (1986) Suppression of the respiratory burst of human monocytes by a synthetic peptide homologous to envelope proteins of human and animal retroviruses. J Immunol 136: 3517–3520.
10. Harris D, Cianciolo G, Snyderman R, Appov S, Koen H (1987) Inhibition of human natural killer cell activity by a synthetic retrovirus homologous to a conserved region in the retroviral protein, p15E. J Immunol 138: 889–894.
11. Mitani M, Cianciolo G, Snyderman R, Yasuda M, Good R, et al. (1987) Suppressive effect on polyclonal B-cell activation of a synthetic peptide homologous to a transmembrane component of oncogenic retroviruses. Proc Natl Acad Sci, USA 84: 237–240.
21. Nelson M, Nelson D (1990) Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide. Cancer Immunol Immunother 30: 331–341.
22. Cianciolo G, Phillips D, Snyderman R (1986) Human malignant and mitogen-transformed cells contain retroviral p15E-related antigen. J Exp Med 159: 964–969.
23. Cerin M, Kahaléh M (2002) Beauty and the beast: The nitric oxide paradox in systemic sclerosis. Rheumatol 41: 843–847.
24. Walford G, Locascio J (2003) Nitric oxide in vascular biology. Thromb Haemostasis 1: 2112–2118.
25. Kolb H, Kolb-Bachofen V (1998) Nitric oxide in autoimmune disease: cytotoxic or regulatory mediator? Immunol Today 19: 356–361.
26. Bouchaire-Hayes D, Alhil H, Kelly C, Barry M, Redmond H, et al. (1997) Nitric oxide attenuates interleukin-2 induced lung injury. Br J Surg 84: 540–542.
27. Sprague R, Stephenson A, McMurd U, Lonigo A (1998) Nitric oxide opposes phorbol ester-induced increases in pulmonary microvascular permeability in vivo. J Pharmacol Exp Ther 288: 435–443.
28. Assar A, Timmons O, Farnühl H, Hoidal J, Michael J (1995) Inhaled nitric oxide decreases the increase in pulmonary vascular permeability after hydrogen peroxide. J Appl Physiol 79: 806–819.
29. Kupatt C, Zahler S, Schumann C, Massoudy P, Becker B, et al. (1996) Nitric oxide mitigates leukocyte adhesion and vascular leak after myocardial ischemia. J Mol Cell Cardiol 28: 643–654.
30. Cerswinka W, Cooper D, Kriegstein C, Feilsch M, Granger D (2002) Nitric oxide-modulates endothelin platelet-leukocyte adhesion in intestinal veins. Amer J Physiol Heart Circ Physiol 282: H1111–H1117.
31. Freedman J, Locasola J, Barnard M, Alpert C, Keaney J, et al. (1997) Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100: 350–356.
32. Gidda J, Park T, Shah A, Gonzales E (1998) Modulation of basal and postischemic leukocyte-endothelial adhesion by nitric oxide. Stroke 29: 1423–1430.
33. Kurosawa I, Wolf R, Grismah M, Granger D (1994) Modulation of ischemia/ reperfusion-induced microvascular dysfunction by nitric oxide. Circ Res 74: 376–382.
34. Cooke J, Dran V (1997) Nitric oxide synthase: role in the genesis of vascular disease. Ann Rev Med 48: 499–509.
35. Kermarrec N, Zunic P, Belousof S, Benesinio J, Drouet L, et al. (1998) Impact of inhaled nitric oxide on platelet aggregation and fibrinolysis in rats with endotoxin lung injury. Am J Respir Care Med 158: 833–839.
36. Lefer A, Lefer D (1996) The role of nitric oxide and cell adhesion molecules on their route of administration. J Immunol 166: 1169–1177.
37. Kupatt C, Zahler S, Schumann C, Massoudy P, Becker B, et al. (1996) Nitric oxide mitigates leukocyte adhesion and vascular leak after myocardial ischemia. J Mol Cell Cardiol 28: 643–654.
38. Cerswinka W, Cooper D, Kriegstein C, Feilsch M, Granger D (2002) Nitric oxide-modulates endothelin platelet-leukocyte adhesion in intestinal veins. Amer J Physiol Heart Circ Physiol 282: H1111–H1117.
39. Freedman J, Locasola J, Barnard M, Alpert C, Keaney J, et al. (1997) Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100: 350–356.
40. Gidda J, Park T, Shah A, Gonzales E (1998) Modulation of basal and postischemic leukocyte-endothelial adhesion by nitric oxide. Stroke 29: 1423–1430.
41. Kurosawa I, Wolf R, Grismah M, Granger D (1994) Modulation of ischemia/ reperfusion-induced microvascular dysfunction by nitric oxide. Circ Res 74: 376–382.
42. Cooke J, Dran V (1997) Nitric oxide synthase: role in the genesis of vascular disease. Ann Rev Med 48: 499–509.
43. Kermarrec N, Zunic P, Belousof S, Benesinio J, Drouet L, et al. (1998) Impact of inhaled nitric oxide on platelet aggregation and fibrinolysis in rats with endotoxin lung injury. Am J Respir Care Med 158: 833–839.
44. Lefer A, Lefer D (1996) The role of nitric oxide and cell adhesion molecules on their route of administration. J Immunol 166: 1169–1177.
45. Kupatt C, Zahler S, Schumann C, Massoudy P, Becker B, et al. (1996) Nitric oxide mitigates leukocyte adhesion and vascular leak after myocardial ischemia. J Mol Cell Cardiol 28: 643–654.
46. Cerswinka W, Cooper D, Kriegstein C, Feilsch M, Granger D (2002) Nitric oxide-modulates endothelin platelet-leukocyte adhesion in intestinal veins. Amer J Physiol Heart Circ Physiol 282: H1111–H1117.
47. Freedman J, Locasola J, Barnard M, Alpert C, Keaney J, et al. (1997) Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100: 350–356.
48. Gidda J, Park T, Shah A, Gonzales E (1998) Modulation of basal and postischemic leukocyte-endothelial adhesion by nitric oxide. Stroke 29: 1423–1430.
49. Kurosawa I, Wolf R, Grismah M, Granger D (1994) Modulation of ischemia/ reperfusion-induced microvascular dysfunction by nitric oxide. Circ Res 74: 376–382.
50. Cooke J, Dran V (1997) Nitric oxide synthase: role in the genesis of vascular disease. Ann Rev Med 48: 499–509.
51. Kermarrec N, Zunic P, Belousof S, Benesinio J, Drouet L, et al. (1998) Impact of inhaled nitric oxide on platelet aggregation and fibrinolysis in rats with endotoxin lung injury. Am J Respir Care Med 158: 833–839.
52. Lefer A, Lefer D (1996) The role of nitric oxide and cell adhesion molecules on their route of administration. J Immunol 166: 1169–1177.
53. Kupatt C, Zahler S, Schumann C, Massoudy P, Becker B, et al. (1996) Nitric oxide mitigates leukocyte adhesion and vascular leak after myocardial ischemia. J Mol Cell Cardiol 28: 643–654.
54. Cerswinka W, Cooper D, Kriegstein C, Feilsch M, Granger D (2002) Nitric oxide-modulates endothelin platelet-leukocyte adhesion in intestinal veins. Amer J Physiol Heart Circ Physiol 282: H1111–H1117.
55. Freedman J, Locasola J, Barnard M, Alpert C, Keaney J, et al. (1997) Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100: 350–356.
56. Gidda J, Park T, Shah A, Gonzales E (1998) Modulation of basal and postischemic leukocyte-endothelial adhesion by nitric oxide. Stroke 29: 1423–1430.
57. Kurosawa I, Wolf R, Grismah M, Granger D (1994) Modulation of ischemia/ reperfusion-induced microvascular dysfunction by nitric oxide. Circ Res 74: 376–382.
58. Cooke J, Dran V (1997) Nitric oxide synthase: role in the genesis of vascular disease. Ann Rev Med 48: 499–509.
59. Kermarrec N, Zunic P, Belousof S, Benesinio J, Drouet L, et al. (1998) Impact of inhaled nitric oxide on platelet aggregation and fibrinolysis in rats with endotoxin lung injury. Am J Respir Care Med 158: 833–839.
60. Lefer A, Lefer D (1996) The role of nitric oxide and cell adhesion molecules on their route of administration. J Immunol 166: 1169–1177.
61. Kupatt C, Zahler S, Schumann C, Massoudy P, Becker B, et al. (1996) Nitric oxide mitigates leukocyte adhesion and vascular leak after myocardial ischemia. J Mol Cell Cardiol 28: 643–654.
62. Cerswinka W, Cooper D, Kriegstein C, Feilsch M, Granger D (2002) Nitric oxide-modulates endothelin platelet-leukocyte adhesion in intestinal veins. Amer J Physiol Heart Circ Physiol 282: H1111–H1117.
63. Freedman J, Locasola J, Barnard M, Alpert C, Keaney J, et al. (1997) Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100: 350–356.
64. Gidda J, Park T, Shah A, Gonzales E (1998) Modulation of basal and postischemic leukocyte-endothelial adhesion by nitric oxide. Stroke 29: 1423–1430.
65. Kurosawa I, Wolf R, Grismah M, Granger D (1994) Modulation of ischemia/ reperfusion-induced microvascular dysfunction by nitric oxide. Circ Res 74: 376–382.
76. Sibata M, Ikeda H, Katumata K, Takeuchi K, Wakisaki A, et al. (1997) Human endogenous retroviruses: expression in various organs in vivo and its regulation in vitro. Leukemia 11: 145–146.
77. Andersson A, Svensson A, Rolny C, Andersson G, Larsson E (1998) Expression of human endogenous retrovirus ERV3 (HERV-R) mRNA in normal and neoplastic tissues. Int J Oncol 12: 309–313.
78. Katsumata K, Ikeda H, Sato M, Ishizu A, Kawarada Y, et al. (1999) Cytokine regulation of env gene expression of human endogenous retrovirus-R in human vascular endothelial cells. Clin Immunol 93: 75–80.
79. Mi S, Lee X, Li X, Veldman G, Finnerty H, et al. (2000) Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature 403: 785–789.
80. Lee X, Keith JJ, Stumm N, Moutsatsos I, McCoy J, et al. (2001) Downregulation of placental syncytin expression and abnormal protein localization in pre-eclampsia. Placenta 22: 808–812.

81. Knerr I, Brindler E, Rascher W (2002) Syncytin, a novel human endogenous retroviral gene in human placenta: evidence for its dysregulation in preeclampsia and HELLP syndrome. Am J Obst Gynecol 186: 210–213.
82. Andersson A, Venables P, Tonjes R, Scherer J, Eriksson L, et al. (2002) Developmental expression of HERV-R (ERV3) and HERV-K in human tissue. Virol 297: 220–225.
83. Keith JJ, Pijnenborg R, van Asche F (2002) Placental syncytin expression in normal and preeclamptic pregnancies. Am J Obst Gynecol 187: 1122–1123.
84. Venables P, Brookes S, Griffiths D, Weiss R, Boyd M (1995) Abundance of an endogenous retroviral envelope protein in placental trophoblasts suggests a biological function. Virol 211: 589–592.
85. Wang J, Chen Z, Cianciolo G, Snyderman R, Brevardi F, et al. (1989) Production of a retroviral p15E-related chemotaxis inhibitor by IL-1-treated endothelial cells. A possible negative feedback in the regulation of the vascular response to monokines. J Immunol 142: 2012–2017.